Sundry Molecules

  • Sergio Canavero
  • Vincenzo Bonicalzi


Several other molecules have been tried for CP. NSAIDs are useless, but tried by the vast majority of patients. Botulinum, which has pleiotropic actions (substance P/CGRP and glutamate block), and may have unexpected central effects, is interesting, but its effects are modest at best. Cholinergics (e.g., donepezil) have not been adequately tested, but may play some role as add-on therapy. Misoprostol (200 μg tid) is effective for MS-related trigeminal neuralgia (e.g., [1]). For other agents, the body of evidence is too thin to make any conclusion.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pfau G, Brinkers M, Treuheit T, Kretzschmar M, Sentürk M, Hachenberg T. Misoprostol as a therapeutic option for trigeminal neuralgia in patients with multiple sclerosis. Pain Med. 2012;13(10):1377–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Ferguson AR, Huie JR, Crown ED, Grau JW. Central nociceptive sensitization vs. spinal cord training: opposing forms of plasticity that dictate function after complete spinal cord injury. Front Physiol. 2012;3:396.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma. 1993;10(1):1–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, Tierney DS, Mason D. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma. 1998;15(10):837–49.CrossRefPubMedGoogle Scholar
  5. 5.
    Han ZA, Song DH, Oh HM, Chung ME. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol. 2016;79:569–78.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hamamci N, Dursun E, Ural C, Cakci A. Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. Br J Clin Pract. 1996;50(7):373–5.PubMedGoogle Scholar
  7. 7.
    Barros TE Jr, Araujo FF, Higino Lda P, Marcon RM, Cristante AF. The effect of monosialoganglyoside (gm-1) administration in spinal cord injury. Acta Ortop Bras. 2016;24(3):123–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Yang ML, Li JJ, So KF, Chen JY, Cheng WS, Wu J, Wang ZM, Gao F, Young W. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal Cord. 2012;50(2):141–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain. J Clin Pharmacol. 2016;56(7):852–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Di Biagio F. Dolore centrale da lesione sopratalamica regredito con atophanyl. Riv Neurol. 1959;29:476–81.Google Scholar
  11. 11.
    Hellwig K, Lukas C, Brune N, Schimrigk S, Przuntek H, Müller T. Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. ScientificWorldJournal. 2006;6:460–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Hans G, Van Maldeghem K, Robert D. Intravenous administration of adenosine (Adenocor) in the treatment of severe, therapy-resistant, central neuropathic pain. Eur J Pain. 2007;11(S1):S145. A326CrossRefGoogle Scholar
  13. 13.
    Humble SR. Calcitonin for acute neuropathic pain associated with spinal cord injury. Anaesth Intensive Care. 2011;39(4):682–6.PubMedGoogle Scholar
  14. 14.
    Kopsky DJ, Amelink GJ, Keppel Hesselink JM. Intractable neuropathic pain in spinal intramedullary cavernoma treated successfully with a novel combination cream. Pain Med. 2012;13(5):729–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Pellicane AJ, Millis SR. Efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of central post-stroke pain: a retrospective analysis. J Pain Res. 2013;6:557–63.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Han ZA, Song DH, Chung ME. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain. Spinal Cord. 2014;52(Suppl 1):S5–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756–63.CrossRefPubMedGoogle Scholar
  19. 19.
    Trbovich M, Yang H. Capsaicin 8% patch for central and peripheral neuropathic pain of persons with incomplete spinal cord injury: two case reports. Am J Phys Med Rehabil. 2015;94:e66–72.CrossRefPubMedGoogle Scholar
  20. 20.
    Batlle L, Mattie R, Irwin R. A medication combination for the treatment of central poststroke pain via the adjuvant use of prednisone with gabapentin: a case report. PM R. 2016;8(3):278–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Camoes-Barbosa A, Neves AF. The analgesic effect of abobotulinum and incobotulinum toxins type A in central poststroke pain: two case reports. PM R. 2016;8(4):384–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sergio Canavero
    • 1
  • Vincenzo Bonicalzi
    • 2
  1. 1.HEAVEN/GEMINI International Collaborative GroupTurinItaly
  2. 2.AOUCittà della Salute e della Scienza di Torino, Department of Neurosciences, Rita Levi MontalciniUniversità di TorinoTurinItaly

Personalised recommendations